Cubist Systematic Strategies LLC acquired a new stake in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 17,707 shares of the specialty pharmaceutical company’s stock, valued at approximately $195,000.
Several other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of SciClone Pharmaceuticals by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 2,540,200 shares of the specialty pharmaceutical company’s stock worth $27,942,000 after acquiring an additional 456,100 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in SciClone Pharmaceuticals during the 2nd quarter worth $2,123,000. State Street Corp increased its holdings in SciClone Pharmaceuticals by 9.8% during the 1st quarter. State Street Corp now owns 1,573,265 shares of the specialty pharmaceutical company’s stock worth $15,423,000 after purchasing an additional 139,877 shares during the period. Menta Capital LLC increased its holdings in SciClone Pharmaceuticals by 9.0% during the 2nd quarter. Menta Capital LLC now owns 431,996 shares of the specialty pharmaceutical company’s stock worth $4,752,000 after purchasing an additional 35,660 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new position in SciClone Pharmaceuticals during the 2nd quarter worth $832,000. 72.80% of the stock is owned by institutional investors and hedge funds.
In other news, CEO Hong Zhao sold 30,000 shares of SciClone Pharmaceuticals stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total value of $330,000.00. Following the transaction, the chief executive officer now directly owns 30,000 shares in the company, valued at approximately $330,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Lan Xie sold 10,000 shares of SciClone Pharmaceuticals stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the transaction, the vice president now owns 10,000 shares in the company, valued at $110,000. The disclosure for this sale can be found here. Company insiders own 5.16% of the company’s stock.
SciClone Pharmaceuticals, Inc. (SCLN) opened at $11.15 on Friday. SciClone Pharmaceuticals, Inc. has a fifty-two week low of $8.55 and a fifty-two week high of $11.43.
SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a return on equity of 20.24% and a net margin of 27.39%. The business had revenue of $44.52 million for the quarter.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
What are top analysts saying about SciClone Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SciClone Pharmaceuticals Inc. and related companies.